Relationship between expression of isocitrate dehydrogenase and clinical outcomes in patients with osteosarcoma
| Project/Area Number |
26670653
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | Yamagata University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TAKAGI Michiaki 山形大学, 医学部・整形外科学講座, 教授 (40241707)
TAKAKUBO Yuya 山形大学, 医学部・整形外科学講座, 講師 (80431641)
SUGAWARA Masato 山形大学, 医学部・整形外科学講座, 助教 (60444030)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 骨肉腫 / イソクエン酸脱水素酵素 / 変異型イソクエン酸デヒドロゲナーゼ / 予後予測因子 |
|---|
| Outline of Final Research Achievements |
Aberration of isocitrate dehydrogenase (IDH) in glioma is a prognosis factor. Osteosarcoma is rare, but is the most common type of primary bone cancer. Association expression of IDH and clinical outcome of osteosarcoma is unknown. We studied relationship between expression of IDH with 5 monoclonal bodies and clinical outcomes in 98 patients with osteosarcoma. Expression of IDH is relative to survival rates and tumor necrosis rates following chemotherapy. Expression of IDH might be a prognosis factor.
|
Report
(3 results)
Research Products
(1 results)
